Xu Liping, Tang Xinyu, Jiang Nan, Zhang Sheng, Cao Yuandong, Sun Xinchen
Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, People's Republic of China.
Cancer Manag Res. 2021 Oct 21;13:8017-8024. doi: 10.2147/CMAR.S334396. eCollection 2021.
Lymphomas of the orbit and ocular adnexa are histologically heterogeneous and their incidence rate has been increasing lately. However, because of their rarity and diversity, few cases have been analyzed. This study evaluated patients with orbital and ocular adnexal mucosa-associated lymphoid tissue (OAMALT), who received radiotherapy, and categorized their clinical characteristics, treatment outcomes, and complications.
We collected data on clinical presentation, age, sex, imaging, tumor location, treatment methods, pathological diagnosis, cataract incidence, cataract incidence periods, overall survival (OS), and disease-free survival (DFS) from 32 patients with orbital involvement and pathologically confirmed marginal zone B-cell lymphoma of MALT who were treated between 2009 and 2018. Twenty-two patients received 20 Gy/10 Fr using intensity-modulated radiation therapy (IMRT) plus 14 Gy/7 Fr using a 6-14-MeV electron beam therapy using a lens-sparing approach. Ten patients received 32 Gy/16 Fr or 34 Gy/17 Fr using IMRT without the lens shield technique. Kaplan-Meier analysis was used to estimate DFS and OS.
The median follow-up time was 83.4 ± 24.5 months. No patient had local recurrence, although three patients developed distant metastases. The 5-year and 10-year OS rates were both 100%. The 5-year and 10-year DFS rates were 96.7% and 74.2%, respectively. Overall, 11 (32.4%) of the 34 lenses developed cataracts. The estimated 5-year, 7-year, and 10-year cumulative cataract rates were 6.9%, 30.9%, and 60.8%, respectively. The median cumulative cataract incidence period was 107.0 months. Age was the only significant parameter associated with cataract formation.
A radiation dose of 32-34 Gy yields excellent local control, DFS, and OS for OAMALT. Some patients may have systemic relapse, and better identification of these patients is necessary. Reducing the prescription radiation dose or using better radiation techniques to spare the ipsilateral lens could reduce cataract formation.
眼眶和眼附属器淋巴瘤在组织学上具有异质性,且其发病率近来一直在上升。然而,由于其罕见性和多样性,很少有病例得到分析。本研究评估了接受放疗的眼眶和眼附属器黏膜相关淋巴组织(OAMALT)患者,并对他们的临床特征、治疗结果和并发症进行分类。
我们收集了2009年至2018年间接受治疗的32例眼眶受累且经病理证实为MALT边缘区B细胞淋巴瘤患者的临床表现、年龄、性别、影像学检查、肿瘤位置、治疗方法、病理诊断、白内障发病率、白内障发病时间、总生存期(OS)和无病生存期(DFS)的数据。22例患者采用调强放射治疗(IMRT)给予20 Gy/10次分割,外加使用6-14 MeV电子束治疗并采用晶状体保护方法给予14 Gy/7次分割。10例患者采用IMRT给予32 Gy/16次分割或34 Gy/17次分割,未使用晶状体防护技术。采用Kaplan-Meier分析来估计DFS和OS。
中位随访时间为83.4±24.5个月。尽管有3例患者发生远处转移,但无患者出现局部复发。5年和10年总生存率均为100%。5年和10年无病生存率分别为96.7%和74.2%。总体而言,34只晶状体中有11只(32.4%)发生了白内障。估计的5年、7年和10年累积白内障发生率分别为6.9%、30.9%和60.8%。白内障累积发病时间的中位数为107.0个月。年龄是与白内障形成相关的唯一显著参数。
32-34 Gy的放射剂量对OAMALT可产生出色的局部控制、DFS和OS。一些患者可能会出现全身复发,因此有必要更好地识别这些患者。降低处方放射剂量或采用更好的放射技术来保护同侧晶状体可减少白内障的形成。